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Abstract
Apolipoprotein E (ApoE) is the strongest genetic risk factor for Alzheimer’s disease and has been implicated in the risk for
other neurological disorders. The three common ApoE isoforms (ApoE2, E3, and E4) each differ by a single amino acid, with
ApoE4 increasing and ApoE2 decreasing the risk of Alzheimer’s disease (AD). Both the isoform and amount of ApoE in the
brain modulate AD pathology by altering the extent of amyloid beta (Ab) peptide deposition. Therefore, quantifying ApoE
isoform production and clearance rates may advance our understanding of the role of ApoE in health and disease. To
measure the kinetics of ApoE in the central nervous system (CNS), we applied in vivo stable isotope labeling to quantify the
fractional turnover rates of ApoE isoforms in 18 cognitively-normal adults and in ApoE3 and ApoE4 targeted-replacement
mice. No isoform-specific differences in CNS ApoE3 and ApoE4 turnover rates were observed when measured in human CSF
or mouse brain. However, CNS and peripheral ApoE isoform turnover rates differed substantially, which is consistent with
previous reports and suggests that the pathways responsible for ApoE metabolism are different in the CNS and the
periphery. We also demonstrate a slower turnover rate for CSF ApoE than that for amyloid beta, another molecule critically
important in AD pathogenesis.
Citation: Wildsmith KR, Basak JM, Patterson BW, Pyatkivskyy Y, Kim J, et al. (2012) In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the
CNS. PLoS ONE 7(6): e38013. doi:10.1371/journal.pone.0038013
Editor: Steven Estus, University of Kentucky, United States of America
Received February 9, 2012; Accepted April 29, 2012; Published June 4, 2012
Copyright:  2012 Wildsmith et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Alzheimer‘s Disease Research (a program of the American Health Assistance Foundation) Grant A2008-345 (KRW and RJB)
and a postdoctoral fellowship (JK); the Hope Center for Neurological Disorders at Washington University (RJB); NIA K23 AG030946 (RJB), AG13956 (DMH), NINDS
RO1-NS065667 (RJB), and NIH-supported UL1 RR024992, TL1 RR024995 and KL2 RR 024994 (ICTS CRU), P30NS069329 (JK) Washington University Biomedical Mass
Spectrometry Research Facility (P30-RR000954, DK020579), Washington University ADRC Genetics Core (P50-AG05681), and Washington University Nutrition
Obesity Research Center (DK056341) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: DMH co-founded C2N Diagnostics, and is on the scientific advisory board of C2N Diagnostics, and Pfizer, and receives grants that did not
support this work from Eli Lilly, Pfizer, and Astra-Zeneca. RJB co-founded C2N Diagnostics and is on the scientific advisory board of C2N Diagnostics and receives
grants that did not support this work from Astrazeneca, and Merck. BWP provides consultation services for tracer turnover kinetics for C2N Diagnostics. KRW now
works for Genentech, which did not provide any funding for this study, and did not have any involvement or influence in data production, data analysis, decision
to publish, or manuscript preparation. None of the above stated competing interests alter the authors’ adherence to all the PLoS ONE policies on sharing data and
materials.
* E-mail: batemanr@neuro.wustl.edu
. These authors contributed equally to this work.
¤ Current address: Genentech, South San Francisco, California, United States of America
Introduction
Apolipoprotein E (ApoE) is a 34 kDa protein which is highly
expressed in the liver and the brain [1]. ApoE is a key regulator of
lipid and cholesterol metabolism and transport. Humans have
three different APOE alleles which result in isoforms of the ApoE
protein differing by one or two amino acids: ApoE2 (cys112,
cys158), ApoE3 (cys112, arg158), and ApoE4 (arg112, arg158).
The prevalence of e2, e3, and e4 alleles in European Americans is
7%, 78%, and 15%, respectively [2]. The amino acid substitutions
affect the total charge and structure of ApoE [2], thereby affecting
its binding to lipoprotein receptors and potentially the lipoprotein
particle stability. ApoE found in the periphery and the central
nervous system (CNS) are independent of each other and
produced from different sources [3]. In the periphery, ApoE is
produced predominantly by the liver and is preferentially found in
VLDL [4]. In the CNS, ApoE is produced by astrocytes and
microglia and is found in HDL-like particles. APOE e4 is currently
the strongest genetic risk factor for developing Alzheimer’s disease
(AD) [5]. Population studies have demonstrated that the e4 allele
increases the risk of developing AD by either 3-fold (1 allele) or 12-
fold (2 alleles) [6], resulting in an earlier age of onset of AD [7,8].
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38013Conversely, the e2 allele decreases the risk for developing AD [9].
In addition to AD, ApoE4 has been associated with increased risk
for other neurological disorders including cerebral amyloid
angiopathy, poor outcome after traumatic brain injury, and
HIV-dementia [10–12]. The mechanism underlying the associa-
tion between ApoE and AD may be related to differential effects of
the ApoE isoforms on Ab fibrillogenesis and clearance [5].
However, the mechanisms underlying the effect of ApoE4 on
other neurological disorders, if they exist, are not known.
Peripheral blood ApoE metabolism is partially understood [13–
17], where ApoE4 is catabolized twice as fast as ApoE3 [15].
However, little is currently known about ApoE turnover kinetics in
the CNS. Due to a lack of in vivo studies, it is unclear whether a
similar isoform-specific effect on ApoE turnover exists in the
human CNS [18–21]. Furthermore, targeted replacement (TR)
mice that possess the human ApoE isoforms substituted into the
mouse gene locus have become popular tools for studying the
effect of ApoE on the pathogenesis of neurologic diseases [5].
These mice express ApoE via the endogenous promoter, and as a
result, the turnover of ApoE should reflect the natural synthesis
and clearance rates of the protein [22]. In particular to AD, the
ApoE TR mice have proven to be useful tools for studying the
effect of the ApoE isoforms on both amyloid b (Ab) deposition and
clearance from the brain [23–26]. Despite considerable attention
given to quantifying brain tissue and cerebrospinal fluid (CSF)
ApoE concentrations [24,27,28], the kinetics of ApoE turnover in
these mice have not been evaluated.
In this study, we quantified the in vivo kinetics of ApoE3 and
ApoE4 in humans and human ApoE TR mice using stable isotope
amino acid labeling coupled with mass spectrometry. For the
human studies, peripheral venous blood and CSF were sampled
during and after in vivo stable isotope labeling with
13C6-leucine
(
13C6-leu). The rate of appearance and disappearance of labeled
ApoE isoforms in each compartment reflects their respective
production and clearance rates. Utilizing an ApoE isoform-specific
liquid chromatography/mass spectrometry (LC/MS) method [29],
we compared ApoE isoform kinetics in both homozygous and
heterozygous subjects in the periphery and CNS. For the mouse
Figure 1. Plasma ApoE Isoforms have different turnover kinetics(ApoE4.ApoE3.ApoE2).
13C6-leu incorporation into plasma ApoE
isoforms was analyzed from a representative individual for each genotype. The
13C6-leu incorporation peaked at 10 h with ApoE4’s maximum
reaching 19.2%, ApoE3 9.9% and ApoE2 4.4%. The different isoforms have different clearance rates as indicated by the slope of the Ln plots (A–D
insets). A–D: A, E3/3; B, E4/4; C, E3/4; D, E2/4 (Blue: E3/E4 LAVYQAGAR, black: E3/E2 LGADMEDVcGR, red: E4 LGADMEDVR, green: E2 cLAVYQAGAR).
doi:10.1371/journal.pone.0038013.g001
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13C6-leu and
analyzed the in vivo kinetics of ApoE3 and ApoE4 by performing
LC/MS analysis on brain homogenates.
Results
ApoE Isoforms in the Periphery have Different Turnover
Rates
Studies have shown that ApoE isoforms have different kinetic
properties in peripheral plasma [13–15]. In order to confirm that
our ApoE isoform-specific LC/MS method yielded similar
findings [29], plasma ApoE samples were analyzed from
individuals labeled with
13C6-leu. CSF and blood were collected
for 48 hours [30,31]. ApoE labeling patterns obtained from an
individual with each ApoE genotype are shown in Figure 1. The
plasma ApoE TTR (tracer to tracee ratio) time course was
characterized by a rapid rise during tracer infusion over 9 hours,
followed by clearance of labeled ApoE. The TTR maximum at
10 h was 20% for ApoE4, 10% for ApoE3 and 4.5% for ApoE2
(Fig. 1) demonstrating that the isoforms have different turnover
rates. The peripheral ApoE compartmental model (Fig. 2A)
provided a strong fit to all sets of ApoE data (Fig. 2B–D). Kinetic
parameters [fractional synthesis rate (FSR), monoexponential
slope fractional clearance rate (FCR), and compartmental model
fractional turnover rate (FTR)] of plasma ApoE are summarized in
Table 1. Differences in ApoE isoform kinetics were found when
each individual isoform was analyzed both between homozygous
subjects and within heterozygous subjects. For example, ApoE4
protein turnover rates in homozygous subjects were approximately
twice as fast the ApoE3 turnover rates in homozygous subjects
(Fig. 1A–B, Table 1). Gregg et al. also observed in homozygotes
that ApoE4 was catabolized 2-fold faster than ApoE3 [15]. Within
the same subject, ApoE4 kinetic rates were double that of ApoE3
kinetic rates (Fig. 1C, Table 1). Furthermore, the LAVYQAGAR
peptide, common to ApoE3 and ApoE4 proteins, exhibited
kinetics that were intermediate between the plasma ApoE3 and
ApoE4 peptides within ApoE3/4 heterozygotes (Table 1). ApoE2
had the slowest turnover rate. The plasma ApoE4 turnover rate
was approximately 4-fold faster than plasma ApoE2 within
ApoE2/4 heterozygotes (Table 1), which is similar to the 3-fold
difference previously reported by Ikewaki et al. [13]. Therefore,
consistent with previously reports [13–15], the plasma ApoE
isoforms have different turnover rates, confirmed here using our
isoform-specific LC/MS technique. ApoE protein levels in plasma
also trended towards being lower in ApoE4 carriers (Table S1).
ApoE Isoforms Display Similar Kinetics in the CNS
To investigate whether a similar trend exists in the CNS,
ApoE2, ApoE3, and ApoE4 kinetics were quantified in CSF using
nanoLC/MS/MS and by monitoring isoform-specific
13C6-
labeled and unlabeled tryptic peptides (E3/2: LGAD-
MEDVc112GR, E4:LGADMEDVR112, E3/4: LAVYQAGAR,
and E2: c158LAVYQAGAR, L indicates site of
13C6 labeling,
variable residues are denoted by subscript, and lower case ‘c’
indicates alkylated) [29]. The CNS ApoE TTR time course was
characterized by a slow sigmoidal rise to a peak at ,25 h (Fig. 3).
The FSR and monoexponential slope FCR were calculated from
the rising and falling portions of the TTR time course,
respectively, for each CNS ApoE isoform-specific peptide (Fig. 3)
and summarized in Table 2. With the exception of the E2/4
Figure 2. Representative compartmental model analyses of
plasma ApoE. A. Peripheral ApoE compartmental model has 4
adjustable parameters: the plasma ApoE FTR, the rate constants for bi-
directional exchange with the non-plasma space, and a scaling factor to
account for isotopic dilution. B. ApoE4 peptide LAVYQAGAR from an
ApoE2/4 subject. C. ApoE3 peptide LGADMEDVcGR from an ApoE3/3
subject. D, ApoE2 peptide cLAVYQAGAR from the same ApoE2/4
subject as in B. Solid line represents model fit to the data.
doi:10.1371/journal.pone.0038013.g002
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ApoE4 p,0.05, Table S2), there were no significant differences
observed in
13C6-leu ApoE isoform peptide labeling, FSR, or FCR
between genotypes. Consistent with this data, we also measured
ApoE levels in the CSF and observed no statistical differences
between genotypes (Table S1). The FSR and monoexponential
slope FCR for the common peptide LAVYQAGAR were
compared across genotypes (Fig. 3E). The average FSR for
CNS-ApoE was 1.5360.31%/h (n=18, LAVYQAGAR) in this
young, cognitively-normal cohort, and the monoexponential slope
FCR was 2.060.42%/h (n=18, LAVYQAGAR).
The whole-system CNS-ApoE FTR was determined by fitting
the full ApoE TTR time course to a compartmental model
(Fig. 4A). Representative modeling curves are depicted in Fig. 4B–
D and average kinetic rates for each genotype, grouped by peptide,
are described in Table 2. The model provided a solid fit to the full
ApoE TTR time course for all data sets (Fig. 4). No significant
differences in kinetic parameters were observed between geno-
types. In particular, there was no significant difference between
ApoE isoform kinetics within either ApoE3/4 or ApoE2/4
heterozygotes. The whole-system FTR was 2.560.4%/h (n=18,
LAVYQAGAR). The monoexponential slope FCR was highly
correlated (R
2=0.71), and the FSR was less well correlated
(R
2=0.31), with the whole-system FTR.
Human ApoE Kinetics in the Mouse Brain
Mice that have been genetically modified to express the human
ApoE isoforms via the endogenous mouse ApoE promoter have
become useful tools for studying the effect of human ApoE
isoforms on various neurological conditions [5]. Several studies
have analyzed ApoE levels in the brains of these mice, but the
results have not been consistent [23,24,27,28,32]. In the current
study, the brain kinetics of ApoE3 and ApoE4 were evaluated by
pulse
13C6-leu labeling mice that were homozygous for either
ApoE3 or ApoE4. The appearance of labeled ApoE in the mouse
brain cortex was then quantified using LC/MS/MS. By plotting
the ratio of labeled ApoE to unlabeled ApoE from the brains of
different mice at various time points following the
13C6-leu pulse
injection, a kinetic time course for ApoE3 and ApoE4 was
obtained (Fig. 5A). ApoE turnover was characterized by a rapid
rise in
13C6-leu labeling for the first hour following tracer injection,
followed by a steady decrease in
13C6-leu labeling for the next
12 hrs. Similar to the analysis of the human data, the mono-
exponential slope FCR was calculated from the decreasing regions
of the TTR time course for each ApoE isoform (Fig. 5B) (ApoE3
6.1960.48%/h, ApoE4 4.8061.12%/h, p=0.2817). No statisti-
cally significant differences were observed between the FCR of
ApoE3 and ApoE4. FSR values were not calculated because there
were not a sufficient number of data points to accurately measure
a linear front-end slope. We also measured brain ApoE levels in
these mice by ELISA, and observed that ApoE4 mice had 12%
less ApoE than ApoE3 mice (Table S1). Since the FCR values
were not different between genotype, the small difference in
protein levels is more likely due to changes in ApoE production.
Therefore, we measured brain ApoE mRNA levels in the mice and
found that ApoE4 mice have 20% lower mRNA levels than
ApoE3 mice (Fig. S1).
ApoE Turnover is Slower than Amyloid Beta Peptide
Turnover in the CNS
It has been proposed that ApoE influences AD pathogenesis
through regulating the clearance of Ab in the brain, potentially
through a direct interaction between Ab and ApoE [5]. We were
therefore interested in comparing the kinetics of ApoE and Ab in
the human brain. CSF TTR time courses for ApoE and Ab were
sequentially obtained from the same samples and compared
during the human experiments (n=4) (Fig. 6A). The Ab kinetics
for these 4 individuals were consistent with previous results
observed in this population [31]. The maximal TTR for Ab was
twice maximal TTR for ApoE with Ab reaching its maximum
enrichment ,8 hours prior to ApoE. The average monoexpo-
nential slope FCR for Ab was 4.5 times greater than for ApoE
(9%/h vs. 2%/h) (Fig. 6).
Discussion
Using in vivo stable isotope labeling we report ApoE isoform
kinetics in the CNS and peripheral circulation from young,
Table 1. Peripheral Plasma ApoE Kinetic Parameters.
Genotype N LGADMEDVcGR (E3/E2) LAVYQAGAR (E3/E4) LGADMEDVR (E4) cLAVYQAGAR (E2)
FSR (h0–4) (%/h)
ApoE 3/3 1 6.9 8.3
ApoE 3/4 1 8.2 8.2 9.0
ApoE 4/4 1 12.3 12.7
ApoE 2/4 1 2.7 14.3 14.6 2.7
Monoexponential slope FCR (h10–19) (%/h)
ApoE 3/3 1 10.5 11.4
ApoE 3/4 1 12.9 18.2 22.9
ApoE 4/4 1 15.2 15.7
ApoE 2/4 1 7.4 19.6 20.6 7.2
Compartmental model FTR (%/h)
ApoE 3/3 1 11.4 14.0
ApoE 3/4 1 15.1 18.2 35.2
ApoE 4/4 1 16.4 16.2
ApoE 2/4 1 5.7 23.1 20.2 4.5
doi:10.1371/journal.pone.0038013.t001
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contrast to peripheral ApoE isoform kinetics, we found no
significant differences in the CNS turnover rates for ApoE3 and
ApoE4 in ApoE3/E4 heterozygotes (Fig. 3). We also observed no
differences between ApoE3 and ApoE4 clearance rates in human
ApoE TR mice (Fig. 5). We did find differences in CNS ApoE2
and ApoE4 FSR and monoexponential FCR (p,0.05, n=2,
Table S2) in ApoE2/E4 individuals; however, this trend was not
reproduced in the FTR (compartmental modeling).
In humans, multiple studies have analyzed the effect of ApoE
isoform status on ApoE protein levels in the CSF [19,23,33–35]
and brain [20,36–38]. However, results from these studies have
not demonstrated any clear trend in ApoE levels, possibly due to
issues with sample stability following collection, antibodies used for
analysis, and heterogeneity in the subject population. Attention
has also been devoted to measuring the ApoE levels in human
ApoE TR mice. Since ApoE is expressed in these mice under the
control of the endogenous mouse APOE gene promoter and
Figure 3.
13C6-leucine labeling in CNS-ApoE isoforms in cognitively-normal young individuals.
13C6-leu incorporation into ApoE isoform-
specific peptides was quantified by nanoLC/MS/MS. The ratios of the labeled to unlabeled ApoE were normalized to the plasma
13C6-leu precursor
levels during the production phase (h0–22) to reduce inter-subject variability due to differential TTR of plasma leucine precursor. Individuals were
grouped by genotype and their averages are shown in A–D: A, E3/3 (n=8); B, E4/4 (n=2); C, E3/4 (n=6); D, E2/4 (n=2) (blue square: LAVYQAGAR,
black circle: LGADMEDVcGR, red triangle: LGADMEDVR, green diamond: cLAVYQAGAR.). The linear regression of the means for h4–16 and h28–44 is
shown for LAVYQAGAR to demonstrate the time points used for each individual’s FSR and monoexponential slope FCR calculations. E. The averages
of the common peptide (LAVYQAGAR) for all four genotypes (n=18) were compared (green circle: E3/3; red triangle: E4/4; blue square: E3/4; black
diamond: E2/4). Error bars represent standard error of the mean (SEM).
doi:10.1371/journal.pone.0038013.g003
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the natural turnover rates of ApoE in the mouse CNS. Several
studies have shown that mice with ApoE3 and ApoE4 have less
total ApoE than mice with ApoE2 [23,24,28,40,41]. However,
other studies have found no differences in the amount of ApoE
between isoforms [27,32]. The reason for these discrepancies is
unclear, but may be due to the use of different ApoE antibodies,
mouse genetic background or tissue lysis conditions.
Since the ApoE protein levels are intrinsically related to the
turnover of ApoE, studying the kinetics of ApoE provides a
mechanistic explanation for the differences, or lack thereof, in
ApoE protein levels in the human CSF and mouse brain. Since we
observed no differences in the FSR, monoexponential slope FCR,
or FTR (compartmental model) of ApoE3 and ApoE4 in the CSF
of humans, our data support the studies that describe no
differences in brain ApoE levels between isoforms. However, the
ability to accurately measure the levels of ApoE in the CNS
remains an important issue that should be resolved. Many studies
measuring the levels of the ApoE isoforms in the CNS rely upon
techniques that use antibodies that might not recognize the
isoforms with equal affinity. Therefore, future studies should
attempt to measure ApoE levels in both the human and mouse
brain using techniques that do not require antibodies, such as
quantitative mass spectrometry.
Our plasma ApoE results are entirely consistent with previous
reports of differential turnover rates for plasma ApoE isoforms
(E4. E3. E2) [13–15]. These results indicate that ApoE turns
over 3- to 6-fold slower in the CNS than the periphery. They also
indicate that the similarity of ApoE isoform kinetics within the
CNS is a result of physiologic and metabolic processes and not an
artifact of our isoform-specific LC/MS method. We also observed
a trend towards decreased levels of ApoE in plasma from E4
carriers (Table S1), consistent with previous results that observe
highest ApoE levels in E2 carriers and lowest in E4 carriers
[42,43]. Since our labeling method confirmed the expected
peripheral ApoE kinetic differences among individuals with
different genotypes, we are confident that the CNS kinetic
measures are valid and reflect physiologic and metabolic ApoE
processing in the CNS.
Given the consistency of our plasma ApoE results with
previous reports, the striking differences between CSF and
plasma ApoE labeling time courses within all 4 individuals
demonstrate that CNS-ApoE synthesis and clearance are largely
independent of peripheral ApoE kinetics (compare Figs. 1 & 3).
These results are consistent with previous findings showing that
plasma and CSF ApoE concentrations are not correlated [44],
and that brain and peripheral ApoE are generated in separate
compartments [3,45].
The FSR and monoexponential slope FCR kinetic parameters
provide simple and convenient indices for ApoE turnover rate, but
these approaches use only a subset of available data points and
utilize assumptions that require validation. The compartmental
models provide a more optimal description of whole-system CNS
or peripheral ApoE kinetics because they provide excellent fits to
the full ApoE TTR time course by incorporating the actual shape
of the plasma
13C6-leu time course and incorporate features
described by the physiology (a long time delay to represent CSF
fluid transport, and a non-plasma exchange compartment for
plasma ApoE). Compartmental models have been derived for
plasma apolipoprotein kinetics [17,46–48], but this is the first
model that describes human CNS-ApoE kinetics.
The CNS ApoE turnover rate in young individuals is 1.5–
2.5%/hour (half-life of ,1 day), which is approximately 4-times
slower than the turnover rate for the total CNS Ab peptide (Fig. 6)
[31], and approximately 10-times slower than CSF turnover [49].
The finding that fractional clearance rates differ for two different
CSF proteins measured in the same person strongly supports the
notion that protein kinetic rates measured in CSF reliably reflect
CNS protein turnover and not just CSF turnover [50]. A slower
CSF ApoE turnover rate compared to amyloid-beta may be
expected given that ApoE recycles into and out of cells.
This stable isotope labeling approach for differentially quanti-
fying protein isoform specific turnover rates may be applied to in
vitro or in vivo model systems and used to inform about differences
Table 2. CNS-ApoE Kinetic Parameters.
Genotype N LGADMEDVcGR (E3/E2) LAVYQAGAR (E3/E4) LGADMEDVR (E4) cLAVYQAGAR (E2)
FSR (h4–16) (%/h)
ApoE 3/3 8 1.5060.39 1.5060.38
ApoE 3/4 6 1.6260.31 1.5860.33 1.5360.46
ApoE 4/4 2 1.4760.13 1.3960.30
ApoE 2/4 2 1.4660.22 1.4860.18 1.4760.14 1.3960.05
Monoexponential slope FCR (h28–44) (%/h)
ApoE 3/3 8 2.1660.52 2.2360.52
ApoE 3/4 6 2.2460.37 2.0660.36 2.7860.92
(n=2*)
ApoE 4/4 2 1.660.11 1.86(n=1*)
ApoE 2/4 2 1.760.56 1.860.20 2.2560.07 1.8260.48
Compartmental model FTR (%/h)
ApoE 3/3 8 2.6460.38 2.5560.47
ApoE 3/4 6 2.7660.55 2.5460.43 2.4060.53
ApoE 4/4 2 2.0860.12 2.5960.29
ApoE 2/4 2 2.6060.16 2.5860.06 2.6860.04 2.4060.53
*Linear fits with r
2,0.8 were excluded from mean calculations.
doi:10.1371/journal.pone.0038013.t002
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isoform-specific turnover rates was observed in this young,
cognitively-normal cohort. However, the possibility remains that
isoform-specific differences could emerge with age or during the
onset and progression of disease. Future studies could use our
labeling methodology to address these possibilities. This approach
could also be used to evaluate the effects of therapeutics on ApoE
production or clearance, such as LXR agonists or agents that
modify ApoE receptor levels.
In vivo stable isotope labeling coupled to an isoform-specific LC/
MS method enabled the first study of ApoE kinetics in the human
CSF. Using a novel multi-compartmental model for CNS, we
quantified CSF ApoE turnover rate to be ,2%/h in young,
cognitively-normal individuals. Our results suggest that there is no
significant difference between the turnover of CNS ApoE3 and
ApoE4 in young, cognitively-normal adults or between ApoE3 and
ApoE4 TR mice. This is in sharp contrast to the ApoE isoform-
specific differences in turnover rates observed in the peripheral
venous blood. We also demonstrate that CNS Ab turnover rate is
roughly 4 times faster than ApoE.
Materials and Methods
Definitions of Samples and Kinetic Compartment
Terminology
To provide a specific and consistent terminology with prior
work, we refer to samples as brain, CSF, or plasma. The CNS in
vivo labeling kinetics not only measure CSF kinetics, but also
account for the site of production (astrocytes in the brain) and all
clearance mechanisms in the brain, ISF, and CSF up to the point
of sample collection [50]. Therefore, we refer to the labeling
kinetic compartment as the CNS compartment. With peripheral
kinetic measures, production and clearance are dependent on
liver, blood, and interacting cells and molecules. Thus, we define
and refer to kinetic compartments as either brain, CNS (including
CSF), or peripheral compartments.
13C6-leucine-ApoE Standards
13C6-leucine-ApoE standards were collected from immortal-
ized mouse astrocytes derived from ApoE knock-in mice
expressing human ApoE2 or ApoE4 [51]. Cells were grown to
near confluency in 10% FBS, 0.2 mg/mL geneticin (Invitrogen,
C a r l s b a d ,C A ) ,1m Ms o d i u mp y r u v a t e ,a n dD M E M ;t h e nt h e
media were changed to serum-free media: DMEM/Ham’s F-12
containing 1% N-2 supplement (Invitrogen), 1 mM sodium
pyruvate, 3 mM 25-hydroxy-cholesterol (Sigma-Aldrich, St.
Louis, MO), and 0–20%
13C6-leucine (
13C6-leu) (105 mg/L,
98%
13C6, Cambridge Isotope Laboratories, Andover, MA).
ApoE-containing serum-free media were collected after 48
hours. Media from ApoE2 and ApoE4 expressing cells were
pooled for use as
13C6-leu enrichment standards as previously
described [29].
Cerebrospinal Fluid (CSF) and Plasma
Human CSF and plasma were collected from healthy young
(22–49 years), cognitively-normal volunteers with a familial history
(parent or grandparent) of AD and enrolled in studies approved by
the Institutional Review Board of Washington University [31].
Figure 4. CNS kinetic modeling curves. A, CNS-ApoE compart-
mental model was used to describe whole-system CNS-ApoE turnover
kinetics. The model is based on data from plasma leucine and CSF-ApoE
TTRs (solid triangles). The plasma leucine TTR time course for a given
subject is used as a ‘‘forcing function’’ to define the tracer availability for
ApoE synthesis. The CNS-ApoE system comprises a delay element and a
compartment that turns over, and accounts for isotopic dilution of the
plasma leucine. The model has 3 adjustable parameters: the shape of
the ApoE TTR time course is modified by adjusting the delay time and
the rate constant for ApoE turnover, and the magnitude of the ApoE
TTR is scaled by varying the degree of isotopic dilution. B–D, A typical
compartmental model analysis from a single, representative, ApoE3/3
subject. B, Plasma leucine TTR remains elevated and does not return to
baseline enrichment immediately after the tracer infusion is halted. C–
D, The ApoE TTR time course exhibits a long time delay and sigmoid
rise to a peak enrichment which is well described by the model. C,
ApoE3 peptide LAVYQAGAR; D, ApoE3 peptide LGADMEDVcGR. Solid
line represents model fit to the data.
doi:10.1371/journal.pone.0038013.g004
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13C6-leu (2 mg/kg/h) for 9 hours
and CSF was collected hourly for 48 h [30,31]. Plasma was
collected hourly for 14 h, followed by collection every odd hour.
ApoE genotype was determined by PCR in the Washington
University ADRC Genetics Core [52].
Isolation of ApoE from CSF or Plasma and Tryptic
Digestion
ApoE was isolated from 0.25 mL CSF and 1.5 mL pooled
ApoE2/E4 astrocyte media using PHM-L liposorb, reduced and
alkylated, and digested with trypsin as described [29]. Plasma
ApoE was prepared as described for CSF with the following
Figure 5. Brain ApoE kinetics in ApoE3 and ApoE4 targeted replacement mice. ApoE was extracted from brains of ApoE3/E3 and ApoE4/E4
mice labeled with
13C6-leucine. Similar kinetics were observed for ApoE3 and ApoE4 mice with monoexponential slopes of 6.260.48%/h and
4.861.12%/h, respectively (blue: ApoE3, black: ApoE4, n=3–6 mice per time point, P =0.2817, error bars represent SEM).
doi:10.1371/journal.pone.0038013.g005
Figure 6. CNS-ApoE has slower kinetics than CNS-Ab. The average of 4 YNC participants’ ApoE and Ab (total)
13C6-leucine enrichment curves
are shown. Ab reaches a higher TTR than ApoE and clears the
13C6-leucine label 46faster than ApoE. ApoE (total:LAVYQAGAR, black circle); Ab (total,
red triangles) (n=4, error bars represent SEM).
doi:10.1371/journal.pone.0038013.g006
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immunoprecipitation with WUE4, a monoclonal total ApoE
antibody [53].
Mouse
13C6-leucine Injection, Tissue Lysis, and ApoE
Isolation
All animal studies were approved by the Animal Studies
Committee of Washington University School of Medicine.
Homozygous PDAPP mice containing the human APP V717F
mutation were generated on a mixed background of DBA/2J,
C57BL/6J, and Swiss Webster (gift from Eli Lilly and Co.). To
generate APP transgenic mouse models with human ApoE,
PDAPP mice were crossed with human APOE knock-in mouse
models in which the endogenous murine APOE gene is replaced
with the APOE3 or APOE4 gene (gift from Dr. Patrick Sullivan,
Duke University) [39]. 3.5 month old ApoE3/E3 and ApoE4/E4
TR mice were injected intraperitoneally with
13C6-leu (200 mg/
kg) and the brain tissue was harvested and plasma collected after
predetermined time points (either 20 min, 40 min, 1, 4, 7, 13, or
19 h). 3–5 mice were used for each time point. One hemisphere of
cortex was then lysed by the addition of 1% triton X-100 lysis
buffer [1% triton X-100, 150 mM NaCl, 50 mM Tris-HCl, 16
complete protease tablet (Roche)], followed by sonication and
centrifugation to remove the tissue debris. ApoE was immuno-
precipitated from the cortex using WUE4 antibody. Briefly,
WUE4 antibody was coupled to Protein G Sepharose 4 Fast Flow
beads (GE Lifesciences) overnight at 4uC and the bound antibody
was cross-linked using dimethyl pimelimidate (20 mM). The tissue
lysate was then incubated with the WUE4- coupled beads O/N at
4uC. The beads were then washed three times with PBS and three
times with triethylammonium bicarbonate (25 mM). The precip-
itated ApoE was then eluted from the beads using formic acid, the
formic acid was removed via vacuum evaporation, and the protein
resuspended in 20% acetonitrile/80% triethylammonium bicar-
bonate. 500 ng of trypsin (Promega) was then added to the
samples and the digest was carried out for 18 h at 37uC.
Identification of MRM Transitions
See supplemental data for detailed LC/MS/MS methods
(Table S3 and Table S4).
NanoLC Tandem MS and Quantitation
Human studies.
13C6-leu labeled and unlabeled ApoE
isoform-specific peptides [LGADMEDVc112GR, LGAD-
MEDVR112, LAVYQAGAR, and c158LAVYQAGAR (‘‘c’’ indi-
cates alkylated cysteine residue M+57)] were separated by reverse
phase on a nanoLC-2D-Ultra (Eksigent Technologies, Dublin,
CA). Peptides were detected by a TSQ Vantage (ThermoFisher
Scientific, San Jose, CA) operating in MRM mode as described in
supplemental data, and quantitated using ThermoFisher’s Xcali-
burH Processing setup and QuanBrowser software (version 2.0.7).
Mouse studies.
13C6-leu labeled and unlabeled ApoE
common peptide SWFEPLVEDMQR was detected by a Xevo
TQ-S (Waters Corporation, Milford, MA) as described in
supplemental data, and quantitated using Waters MassLynx 4.1
software. Human and mouse LC-MS results were exported to
Microsoft Office Excel spreadsheets and GraphpadPrism5 for
further statistical analyses.
Fractional Synthesis Rate (FSR) and Fractional Clearance
Rate (FCR) Calculations
Plasma
13C6-leu tracer to trace ratio (TTR) (the molar ratio of
labeled to unlabeled species) was determined using GC/MS [54],
and used to represent the precursor pool enrichment for ApoE
synthesis. The FSR of ApoE isoforms was calculated by dividing
the slope of the linear regression during the incorporation phase of
ApoE (h4–16 for CSF, and h0–4 for plasma) by the average
plateau of free
13C6-leu enrichment in plasma [31,55]. For the
mouse studies, FSR curves were generated using the 20 min and
40 min labeled/unlabeled ApoE values that had been normalized
to plasma
13C6-leu values obtained from the 20 min time point.
The ApoE isoform monoexponential slope FCR was calculated
using the natural log slope for the clearance portion (h28–44 for
CSF, and h10–19 for plasma) of the ApoE TTR time course [31].
For the mouse studies, the clearance portion of the curve was
considered to be 1 to 13 hrs.
Compartmental Modeling
Compartmental modeling was performed using the SAAM II
program (SAAM institute, University of Washington, Seattle).
The fractional turnover rate (FTR) of peripheral plasma ApoE
was determined using a compartmental model (Fig. 2A) that
features a plasma leucine precursor pool, a plasma ApoE pool
that turns over, and a non-plasma exchange compartment that
is required to completely account for the shape of the time
course. The model used each subject’s measured plasma
13C6-
leu TTR time course and accounted for isotopic dilution
between plasma leucine and ApoE production. The plasma
ApoE FTR is the rate constant for irreversible loss of ApoE.
The model used for CNS ApoE (Fig. 4A) is based on a model
routinely used for very low density lipoprotein apoB-100
turnover kinetics [56]. The model described the shape of the
ApoE TTR time course as a combination of a delay and a
turning over compartment. The residence time (RT) of ApoE in
the whole system was calculated as the sum of the RT for the
delay and turnover compartments, and the whole-system FTR
was calculated as the inverse of whole-system RT.
Statistical Analysis
CSF results were analyzed by a repeated measure analyses of
variance(ANOVA)inwhichgenotypesarebetweensubjectsandthe
peptides are within group factors. For the mouse studies, statistical
significancebetweenthetwogenotypeswascalculatedusinganalysis
of covariance (ANCOVA) for the FSR and FCR slopes.
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